Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Current Deferred Revenue (2017 - 2025)

Regen BioPharma (RGBP) has disclosed Current Deferred Revenue for 5 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue fell 8.83% to $1.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 million, a 8.83% decrease, with the full-year FY2025 number at $1.3 million, down 8.64% from a year prior.
  • Current Deferred Revenue was $1.3 million for Q4 2025 at Regen BioPharma, down from $1.3 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $1.9 million in Q2 2021 to a low of $1.3 million in Q4 2025.
  • A 3-year average of $1.5 million and a median of $1.4 million in 2025 define the central range for Current Deferred Revenue.
  • Biggest YoY gain for Current Deferred Revenue was 8.64% in 2025; the steepest drop was 8.83% in 2025.
  • Regen BioPharma's Current Deferred Revenue stood at $1.9 million in 2021, then fell by 23.58% to $1.4 million in 2024, then decreased by 8.83% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for RGBP's Current Deferred Revenue are $1.3 million (Q4 2025), $1.3 million (Q3 2025), and $1.4 million (Q2 2025).